Morsicatio Labiorum/Linguarum - Three Cases Report and a Review of the Literature
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Use of Biologic Agents in the Treatment of Oral Lesions Due to Pemphigus and Behçet's Disease: a Systematic Review
Davis GE, Sarandev G, Vaughan AT, Al-Eryani K, Enciso R. The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review. J Anesthesiol & Pain Therapy. 2020;1(1):14-23 Systematic Review Open Access The Use of Biologic Agents in the Treatment of Oral Lesions due to Pemphigus and Behçet’s Disease: A Systematic Review Gerald E. Davis II1,2, George Sarandev1, Alexander T. Vaughan1, Kamal Al-Eryani3, Reyes Enciso4* 1Advanced graduate, Master of Science Program in Orofacial Pain and Oral Medicine, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 2Assistant Dean of Academic Affairs, Assistant Professor, Restorative Dentistry, Meharry Medical College, School of Dentistry, Nashville, Tennessee, USA 3Assistant Professor of Clinical Dentistry, Division of Periodontology, Dental Hygiene & Diagnostic Sciences, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA 4Associate Professor (Instructional), Division of Dental Public Health and Pediatric Dentistry, Herman Ostrow School of Dentistry of USC, Los Angeles, California, USA Article Info Abstract Article Notes Background: Current treatments for pemphigus and Behçet’s disease, such Received: : March 11, 2019 as corticosteroids, have long-term serious adverse effects. Accepted: : April 29, 2020 Objective: The objective of this systematic review was to evaluate the *Correspondence: efficacy of biologic agents (biopharmaceuticals manufactured via a biological *Dr. Reyes Enciso, Associate Professor (Instructional), Division source) on the treatment of intraoral lesions associated with pemphigus and of Dental Public Health and Pediatric Dentistry, Herman Ostrow Behçet’s disease compared to glucocorticoids or placebo. School of Dentistry of USC, Los Angeles, California, USA; Email: [email protected]. -
Zeroing in on the Cause of Your Patient's Facial Pain
Feras Ghazal, DDS; Mohammed Ahmad, Zeroing in on the cause MD; Hussein Elrawy, DDS; Tamer Said, MD Department of Oral Health of your patient's facial pain (Drs. Ghazal and Elrawy) and Department of Family Medicine/Geriatrics (Drs. Ahmad and Said), The overlapping characteristics of facial pain can make it MetroHealth Medical Center, Cleveland, Ohio difficult to pinpoint the cause. This article, with a handy at-a-glance table, can help. [email protected] The authors reported no potential conflict of interest relevant to this article. acial pain is a common complaint: Up to 22% of adults PracticE in the United States experience orofacial pain during recommendationS F any 6-month period.1 Yet this type of pain can be dif- › Advise patients who have a ficult to diagnose due to the many structures of the face and temporomandibular mouth, pain referral patterns, and insufficient diagnostic tools. disorder that in addition to Specifically, extraoral facial pain can be the result of tem- taking their medication as poromandibular disorders, neuropathic disorders, vascular prescribed, they should limit disorders, or atypical causes, whereas facial pain stemming activities that require moving their jaw, modify their diet, from inside the mouth can have a dental or nondental cause and minimize stress; they (FIGURE). Overlapping characteristics can make it difficult to may require physical therapy distinguish these disorders. To help you to better diagnose and and therapeutic exercises. C manage facial pain, we describe the most common causes and underlying pathological processes. › Consider prescribing a tricyclic antidepressant for patients with persistent idiopathic facial pain. C Extraoral facial pain Extraoral pain refers to the pain that occurs on the face out- 2-15 Strength of recommendation (SoR) side of the oral cavity. -
White Lesions of the Oral Cavity and Derive a Differential Diagnosis Four for Various White Lesions
2014 self-study course four course The Ohio State University College of Dentistry is a recognized provider for ADA, CERP, and AGD Fellowship, Mastership and Maintenance credit. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to ADA CERP at www.ada.org/goto/cerp. The Ohio State University College of Dentistry is approved by the Ohio State Dental Board as a permanent sponsor of continuing dental education ABOUT this FREQUENTLY asked COURSE… QUESTIONS… Q: Who can earn FREE CE credits? . READ the MATERIALS. Read and review the course materials. A: EVERYONE - All dental professionals in your office may earn free CE contact . COMPLETE the TEST. Answer the credits. Each person must read the eight question test. A total of 6/8 course materials and submit an questions must be answered correctly online answer form independently. for credit. us . SUBMIT the ANSWER FORM Q: What if I did not receive a ONLINE. You MUST submit your confirmation ID? answers ONLINE at: A: Once you have fully completed your p h o n e http://dent.osu.edu/sterilization/ce answer form and click “submit” you will be directed to a page with a . RECORD or PRINT THE 614-292-6737 unique confirmation ID. CONFIRMATION ID This unique ID is displayed upon successful submission Q: Where can I find my SMS number? of your answer form. -
Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002
Department of Health & Medicare Human Services (DHHS) Centers for Medicare & Coverage Issues Manual Medicaid Services (CMS) Transmittal 155 Date: MAY 1, 2002 CHANGE REQUEST 2149 HEADER SECTION NUMBERS PAGES TO INSERT PAGES TO DELETE Table of Contents 2 1 45-30 - 45-31 2 2 NEW/REVISED MATERIAL--EFFECTIVE DATE: October 1, 2002 IMPLEMENTATION DATE: October 1, 2002 Section 45-31, Intravenous Immune Globulin’s (IVIg) for the Treatment of Autoimmune Mucocutaneous Blistering Diseases, is added to provide limited coverage for the use of IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid (a.k.a., Cicatricial Pemphigoid), and (5) Epidermolysis Bullosa Acquisita. Use J1563 to bill for IVIg for the treatment of biopsy-proven (1) Pemphigus Vulgaris, (2) Pemphigus Foliaceus, (3) Bullous Pemphigoid, (4) Mucous Membrane Pemphigoid, and (5) Epidermolysis Bullosa Acquisita. This revision to the Coverage Issues Manual is a national coverage decision (NCD). The NCDs are binding on all Medicare carriers, intermediaries, peer review organizations, health maintenance organizations, competitive medical plans, and health care prepayment plans. Under 42 CFR 422.256(b), an NCD that expands coverage is also binding on a Medicare+Choice Organization. In addition, an administrative law judge may not review an NCD. (See §1869(f)(1)(A)(i) of the Social Security Act.) These instructions should be implemented within your current operating budget. DISCLAIMER: The revision date and transmittal number only apply to the redlined material. All other material was previously published in the manual and is only being reprinted. CMS-Pub. -
Prevalence of Oral Lesions in Complete Denture Wearers- an Original Research
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 20, Issue 1 Ser.3 (January. 2021), PP 29-33 www.iosrjournals.org Prevalence of oral lesions in complete denture wearers- An original research Prenika Sharma1*, Reecha Gupta2 1- MDS, Oral medicine and radiology 2- Professor and HOD Department of Prosthodontics, Indira Gandhi Govt. Dental College, Jammu (J&K) Abstract: Background: Complete denture patients are often associated with the various denture-related oral mucosallesions. The purpose of this study is to evaluate the prevalence ofdenture-related oral mucosal lesions in complete denture patients. Materials and Methods: The study was consisted of 225 patientshaving various denture-induced oral mucosal lesions from theoutpatient department of the department out of the 395 completedenture patients examined. Data related to gender, age, length ofdenture use, hygiene care were obtained. All the data were tabulated and analyzed. Results: In 225 complete denture patients. Denture stomatitis (60.23%) was the most commonlesion present, followed by Epulis fissuratum and angularcheilitis. The denture-induced oral mucosal lesions werefound more common in age >40 years (59.78%) and in female(52.70%) complete denture wearer patients. Conclusion: The present studies showed that oral lesions associated with wearing denture are prevalent and create health problems that impact the quality of life of dental patients. Key Words: Complete denture, denture stomatitis, Epulis fissuratum, oralmucosal lesions. --------------------------------------------------------------------------------------------------------------------------------------- Date of Submission: 26-12-2020 Date of Acceptance: 07-01-2021 --------------------------------------------------------------------------------------------------------------------------------------- I. Introduction Edentulism may be the last sequel of periodontal diseases and dental caries. In case of older adults, edentulism is essential as a correlate of self-esteem and quality of life. -
Vivid Dreams/ Problems Sleeping: Nausea/Upset Stomach: Itching/Rash
Addressing NRT Barriers • Assess the severity of symptoms (Is it tolerable?). • Assess Hx: onset, duration and any troubleshooting that has already taken place. If indicated, get history of these symptoms when not taking these medications. You may also ask how Pt. would normally treat these symptoms. • If symptoms are tolerable àdevelop troubleshooting plan with Pt. Inform Pt. that many symptoms will go away after a few days. Reassess at next visit, but ask Pt. to call if symptoms persist/worsen or become intolerable before next call/visit. • If symptoms are not tolerableàconsider changing products or dosages as applicable. Consult study physician, as needed. Refer Pt. to their personal physician, if needed (e.g., prescription strength creams). • All potential cardiac symptoms should be promptly reported to study physician. Advise Pt. to discontinue NRT when indicated or instructed by study physician. Vivid Dreams/ Problems Sleeping: - Assess if sleep is being disrupted. Is night waking normal for Pt. – what is Pts.’ normal routine? - May try taking patch off at night, keeping in mind cravings may be stronger in the AM. After a couple of nights, try again to wear patch overnight. If using more than 1 patch, may consider only wearing 1 at night. - May try removing patch at night and putting on 2 hours before waking, especially when early morning waking is part of routine. Otherwise, can set an alarm, put on patch, and go back to sleep. - Regulate eating and sleeping patterns and use sleep hygiene tips (relaxation training, avoid caffeine). - Do not smoke or use short-acting NRT within 1-2 hours of bedtime (especially if sleep initiation is the major complaint.) Nausea/upset stomach: - Ask if nausea is only after using gum/lozenge or also after smoking a cigarette. -
Facial Image Comparison Feature List for Morphological Analysis
Disclaimer: As a condition to the use of this document and the information contained herein, the Facial Identification Scientific Working Group (FISWG) requests notification by e-mail before or contemporaneously to the introduction of this document, or any portion thereof, as a marked exhibit offered for or moved into evidence in any judicial, administrative, legislative, or adjudicatory hearing or other proceeding (including discovery proceedings) in the United States or any foreign country. Such notification shall include: 1) the formal name of the proceeding, including docket number or similar identifier; 2) the name and location of the body conducting the hearing or proceeding; and 3) the name, mailing address (if available) and contact information of the party offering or moving the document into evidence. Subsequent to the use of this document in a formal proceeding, it is requested that FISWG be notified as to its use and the outcome of the proceeding. Notifications should be sent to: Redistribution Policy: FISWG grants permission for redistribution and use of all publicly posted documents created by FISWG, provided the following conditions are met: Redistributions of documents, or parts of documents, must retain the FISWG cover page containing the disclaimer. Neither the name of FISWG, nor the names of its contributors, may be used to endorse or promote products derived from its documents. Any reference or quote from a FISWG document must include the version number (or creation date) of the document and mention if the document is in a draft status. Version 2.0 2018.09.11 Facial Image Comparison Feature List for Morphological Analysis 1. -
Oral Manifestations of Systemic Disease Their Clinical Practice
ARTICLE Oral manifestations of systemic disease ©corbac40/iStock/Getty Plus Images S. R. Porter,1 V. Mercadente2 and S. Fedele3 provide a succinct review of oral mucosal and salivary gland disorders that may arise as a consequence of systemic disease. While the majority of disorders of the mouth are centred upon the focus of therapy; and/or 3) the dominant cause of a lessening of the direct action of plaque, the oral tissues can be subject to change affected person’s quality of life. The oral features that an oral healthcare or damage as a consequence of disease that predominantly affects provider may witness will often be dependent upon the nature of other body systems. Such oral manifestations of systemic disease their clinical practice. For example, specialists of paediatric dentistry can be highly variable in both frequency and presentation. As and orthodontics are likely to encounter the oral features of patients lifespan increases and medical care becomes ever more complex with congenital disease while those specialties allied to disease of and effective it is likely that the numbers of individuals with adulthood may see manifestations of infectious, immunologically- oral manifestations of systemic disease will continue to rise. mediated or malignant disease. The present article aims to provide This article provides a succinct review of oral manifestations a succinct review of the oral manifestations of systemic disease of of systemic disease. It focuses upon oral mucosal and salivary patients likely to attend oral medicine services. The review will focus gland disorders that may arise as a consequence of systemic upon disorders affecting the oral mucosa and salivary glands – as disease. -
Features of Reactive White Lesions of the Oral Mucosa
Head and Neck Pathology (2019) 13:16–24 https://doi.org/10.1007/s12105-018-0986-3 SPECIAL ISSUE: COLORS AND TEXTURES, A REVIEW OF ORAL MUCOSAL ENTITIES Frictional Keratosis, Contact Keratosis and Smokeless Tobacco Keratosis: Features of Reactive White Lesions of the Oral Mucosa Susan Müller1 Received: 21 September 2018 / Accepted: 2 November 2018 / Published online: 22 January 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract White lesions of the oral cavity are quite common and can have a variety of etiologies, both benign and malignant. Although the vast majority of publications focus on leukoplakia and other potentially malignant lesions, most oral lesions that appear white are benign. This review will focus exclusively on reactive white oral lesions. Included in the discussion are frictional keratoses, irritant contact stomatitis, and smokeless tobacco keratoses. Leukoedema and hereditary genodermatoses that may enter in the clinical differential diagnoses of frictional keratoses including white sponge nevus and hereditary benign intraepithelial dyskeratosis will be reviewed. Many products can result in contact stomatitis. Dentrifice-related stomatitis, contact reactions to amalgam and cinnamon can cause keratotic lesions. Each of these lesions have microscopic findings that can assist in patient management. Keywords Leukoplakia · Frictional keratosis · Smokeless tobacco keratosis · Stomatitis · Leukoedema · Cinnamon Introduction white lesions including infective and non-infective causes will be discussed -
Bullous Pemphigoid/Pemphigus and Administration of the Pfizer/Biontech Vaccine (Comirnaty®). Introduction the Pfizer/Bionte
Bullous Pemphigoid/Pemphigus and administration of the Pfizer/BioNTech vaccine (Comirnaty®). Introduction The Pfizer/BioNTech vaccine (Comirnaty®) is a COVID-19-mRNA-vaccine (nucleoside modified). It is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 16 years of age and older. [1] The nucleoside-modified messenger RNA in Comirnaty® is formulated in lipid nanoparticles, which enable delivery of the nonreplicating RNA into host cells to direct transient expression of the SARS-CoV-2 S antigen. The mRNA codes for membrane-anchored, full-length Spike glycoprotein with two point mutations within the central helix. [1] Comirnaty® has been registered in Europe since December 21st, 2020. Bullous skin diseases are a group of dermatoses characterized by blisters and bullae in the skin and mucous membranes. The most common are pemphigus and bullous pemphigoid (BP). Pemphigus and bullous pemphigoid are autoantibody-mediated blistering skin diseases. In pemphigus, keratinocytes in epidermis and mucous membranes lose cell-cell adhesion, and in pemphigoid, the basal keratinocytes lose adhesion to the basement membrane. Bullous pemphigoid is a more common disease than pemphigus [2]. Bullous pemphigoid is the most common heterogeneous subepidermal autoimmune blistering disease (incidence 7 per million person year) [3,4], with an increasing prevalence after the age of 70, although it can also occur in the younger. It is characterized by auto-antibodies against different structural proteins of the hemidesmosomes in the epidermal basement membrane zone (EBMZ). Bullous pemphigoid typically causes severe pruritus with predominantly cutaneous lesions consisting of tense (fluid filled) bullae, erythema, and urticarial plaques. -
White Sponge Nevus
Scholars Journal of Applied Medical Sciences (SJAMS) ISSN 2320-6691 (Online) Abbreviated Key Title: Sch. J. App. Med. Sci. ISSN 2347-954X (Print) ©Scholars Academic and Scientific Publisher A Unit of Scholars Academic and Scientific Society, India Dental Medicine www.saspublisher.com White Sponge Nevus: Report of Case And Literature Review Hasni W1,2*, Hassouna MO1, Slim A1, Ben Massoud N1,2, Ben Youssef S1,2, Abdelatif B1,2 1Oral Surgery Unit, Dental Medicine Department, University Hospital Farhat Hached, Sousse, University of Monastir, Tunisia North Africa 2Research Laboratory: Functional and Aesthetic Rehabilitation of Maxillary (LR 12SP10) , Tunisia North Africa Abstract: White sponge nevus (WSN) is a rare benign autosomal dominant disorder. Case Report To date, a few hundred cases have been reported worldwide. It is usually manifested as white, soft, and spongy plaque involving the mucous membrane, predominantly the *Corresponding author oral mucosa. Careful clinical and histopathological examination is recommended to Hasni W exclude other more serious disorder presenting as oral white lesions. Herein, we present the second Tunisian case of oral WSN in an 18-year-old female with no Article History familial background. Current approaches in literature to the diagnosis and treatment Received: 20.10.2018 were also studied. Accepted: 28.10.2018 Keywords: Oral mucosa, Hereditary Mucosal Leukokeratosis, White lesion, white Published: 30.10.2018 sponge nevus. DOI: INTRODUCTION 10.21276/sjams.2018.6.10.88 White sponge nevus (WSN) is a rare, benign condition affecting the mucous membranes. It was first described by Hyde in 1909 but the term WSN was introduced by Canon in 1935 [1, 2].It is an autosomal dominant mucosal disorder that affects non keratinizing stratified epithelia, primarily the oral mucosa. -
GLOSSARY of MEDICAL and ANATOMICAL TERMS
GLOSSARY of MEDICAL and ANATOMICAL TERMS Abbreviations: • A. Arabic • abb. = abbreviation • c. circa = about • F. French • adj. adjective • G. Greek • Ge. German • cf. compare • L. Latin • dim. = diminutive • OF. Old French • ( ) plural form in brackets A-band abb. of anisotropic band G. anisos = unequal + tropos = turning; meaning having not equal properties in every direction; transverse bands in living skeletal muscle which rotate the plane of polarised light, cf. I-band. Abbé, Ernst. 1840-1905. German physicist; mathematical analysis of optics as a basis for constructing better microscopes; devised oil immersion lens; Abbé condenser. absorption L. absorbere = to suck up. acervulus L. = sand, gritty; brain sand (cf. psammoma body). acetylcholine an ester of choline found in many tissue, synapses & neuromuscular junctions, where it is a neural transmitter. acetylcholinesterase enzyme at motor end-plate responsible for rapid destruction of acetylcholine, a neurotransmitter. acidophilic adj. L. acidus = sour + G. philein = to love; affinity for an acidic dye, such as eosin staining cytoplasmic proteins. acinus (-i) L. = a juicy berry, a grape; applied to small, rounded terminal secretory units of compound exocrine glands that have a small lumen (adj. acinar). acrosome G. akron = extremity + soma = body; head of spermatozoon. actin polymer protein filament found in the intracellular cytoskeleton, particularly in the thin (I-) bands of striated muscle. adenohypophysis G. ade = an acorn + hypophyses = an undergrowth; anterior lobe of hypophysis (cf. pituitary). adenoid G. " + -oeides = in form of; in the form of a gland, glandular; the pharyngeal tonsil. adipocyte L. adeps = fat (of an animal) + G. kytos = a container; cells responsible for storage and metabolism of lipids, found in white fat and brown fat.